Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
Add more filters










Publication year range
1.
Int J Qual Health Care ; 10(1): 15-26, 1998 Feb.
Article in English | MEDLINE | ID: mdl-10030783

ABSTRACT

OBJECTIVE: To determine the clinical and financial outcomes of a highly structured multidisciplinary care model for patients in an intensive care unit (ICU) who require prolonged mechanical ventilation. The structured model outcomes (protocol group) are compared with the preprotocol outcomes. DESIGN: Descriptive study with financial analysis. SETTING: A twelve-bed medical-surgical ICU in a non-teaching tertiary referral center in Ogden, Utah. STUDY PARTICIPANTS: During a 54 month period, 469 consecutive intensive care patients requiring mechanical ventilation for longer than 72 hours who did not meet exclusion criteria were studied. INTERVENTIONS: A multidisciplinary team was formed to coordinate the care of ventilator-dependent patients. Care was integrated by daily collaborative bedside rounds, monthly meetings, and implementation of numerous guidelines and protocols. Patients were followed from the time of ICU admission until the day of hospital discharge. MAIN OUTCOME MEASURES: Patients were assigned APACHE II scores on admission to the ICU, and were divided into eight diagnostic categories. ICU length of stay, hospital length of stay, costs, charges, reimbursement, and in-hospital mortality were measured. RESULTS: Mortality in the preprotocol and protocol group, after adjustment for APACHE II scores, remained statistically unchanged (21-23%). After we implemented the new care model, we demonstrated significant decreases in the mean survivor's ICU length of stay (19.8 days to 14.7 days, P= 0.001), hospital length of stay (34.6 days to 25.9 days, P=0.001), charges (US$102500 to US$78500, P=0.001), and costs (US$71900 to US$58000, P=0.001). CONCLUSIONS: Implementation of a structured multidisciplinary care model to care for a heterogeneous population of ventilator-dependent ICU patients was associated with significant reductions in ICU and hospital lengths of stay, charges, and costs. Mortality rates were unaffected.


Subject(s)
Critical Care/organization & administration , Length of Stay , Outcome Assessment, Health Care , Patient Care Team , Respiration, Artificial/economics , APACHE , Adult , Aged , Chronic Disease , Costs and Cost Analysis , Critical Care/classification , Critical Care/economics , Female , Humans , Intensive Care Units/economics , Intensive Care Units/statistics & numerical data , Linear Models , Male , Middle Aged , Models, Theoretical , Prospective Studies , Respiration, Artificial/mortality , Utah
2.
Mol Pharmacol ; 45(6): 1253-8, 1994 Jun.
Article in English | MEDLINE | ID: mdl-8022417

ABSTRACT

A series of selective antiherpetic compounds were found to exert pronounced cytostatic activity against herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) thymidine kinase (TK) gene-transfected mammary carcinoma FM3A cells. Based on their potency and mechanism of cytostatic action, the antiherpetic compounds could be divided into two different classes. The first class encompasses (E)-5-(2-bromovinyl)-2'-deoxyuridine and structurally related analogues thereof [i.e., the cytosine derivative (E)-5-(2-bromovinyl)-2'-deoxycytidine and the 4'-thio derivative (E)-5-(2-bromovinyl)-2'-deoxy-4'-thiouridine]. These compounds are exquisitely cytostatic against FM3A/TK-/HSV-1 TK+ and FM3A/TK-/HSV-2 TK+ cells (50% inhibitory concentrations ranging from 0.047 to 0.001 microM) and inhibit tumor cell proliferation by inhibiting cellular thymidylate synthase. The second class consists of the acyclic guanosine derivatives penciclovir, buciclovir, and ganciclovir. These compounds are also more inhibitory to the HSV-1 TK or HSV-2 TK gene-transfected FM3A cells than to FM3A/0 or FM3A/TK- cells, but at concentrations that are higher than the concentrations at which the (E)-5-(2-bromovinyl)-2'-deoxyuridine derivatives proved to be inhibitory. These acyclic guanosine analogues appear to be targeted at the cellular DNA polymerase. From this study, (E)-5-(2-bromovinyl)-2'-deoxy-4'-thiouridine emerged as a promising candidate compound for the treatment of HSV-1 TK gene-transfected tumors in vivo, due to its metabolic stability (i.e., resistance to hydrolysis by thymidine phosphorylase).


Subject(s)
Antiviral Agents/pharmacology , Herpesvirus 1, Human/enzymology , Herpesvirus 2, Human/enzymology , Thymidine Kinase/genetics , Transfection , Animals , Bromodeoxycytidine/analogs & derivatives , Bromodeoxycytidine/pharmacology , Bromodeoxyuridine/analogs & derivatives , Bromodeoxyuridine/pharmacology , Cell Survival/drug effects , Genetic Therapy , Herpesvirus 1, Human/drug effects , Herpesvirus 1, Human/physiology , Herpesvirus 2, Human/drug effects , Herpesvirus 2, Human/physiology , Humans , Mice , Mice, Inbred C3H , Substrate Specificity , Thiouridine/analogs & derivatives , Thiouridine/pharmacology , Thymidine Phosphorylase/metabolism , Thymidylate Synthase/antagonists & inhibitors , Tumor Cells, Cultured , Virus Replication/drug effects
3.
J Biol Chem ; 269(11): 8036-43, 1994 Mar 18.
Article in English | MEDLINE | ID: mdl-8132526

ABSTRACT

Several novel 5-substituted 2'-deoxyuridine (dUrd) analogues were evaluated as substrates for highly purified herpes simplex virus type 1 (HSV-1)-encoded thymidine kinase (TK) derived from HSV-1 TK gene-transfected murine mammary carcinoma FM3A cells, and human platelet thymidine (dThd) phosphorylase. The Ki of 5-(furan-2-yl)-dUrd, 5-(thien-2-yl)-dUrd and 5-(thien-2-yl)-dCyd for HSV-1 TK was 0.94, 0.71, and 1.32 microM, respectively. Inhibition was competitive with respect to the natural substrate dThd. With dCyd as substrate, the Ki of 5-(thien-2-yl)-dCyd for HSV-1 TK was 4.5 microM (Ki/Km = 0.17). In striking contrast with (E)-5-(2-bromovinyl)-dUrd, the 5-(thien-2-yl)- and 5-(furan-2-yl)-dUrd derivatives were not substrates for human dThd phosphorylase. 5-(Thien-2-yl)-dUrd, 5-(furan-2-yl)-dUrd and 5-(thien-2-yl)-dCyd were at least 100-fold more cytostatic to the HSV TK gene-transfected FM3A tumor cells than wild-type FM3A/0 cells. The viral TK expressed in the HSV-1 TK gene-transfected tumor cells merely acts as an activating enzyme, whereas thymidylate synthase serves as the target enzyme for the cytostatic action of the compounds. The novel 5-substituted dUrd analogues should be further pursued as candidate drugs in the treatment of HSV TK gene-transfected tumors.


Subject(s)
Antimetabolites, Antineoplastic/toxicity , Herpesvirus 1, Human/enzymology , Pyrimidine Nucleosides/toxicity , Thymidine Kinase/biosynthesis , Animals , Cell Division/drug effects , Cell Line , Cell Survival/drug effects , Chromatography , Chromatography, Affinity , Chromatography, Ion Exchange , Cytosol/enzymology , DNA, Neoplasm/biosynthesis , DNA, Neoplasm/drug effects , Durapatite , Female , Herpesvirus 1, Human/genetics , Kinetics , Mammary Neoplasms, Experimental , Mice , Mice, Inbred C3H , Structure-Activity Relationship , Thymidine Kinase/antagonists & inhibitors , Thymidine Kinase/isolation & purification , Transfection , Tumor Cells, Cultured
4.
J Biol Chem ; 268(33): 24591-8, 1993 Nov 25.
Article in English | MEDLINE | ID: mdl-7901217

ABSTRACT

EICAR (5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide) is a cytostatic agent that inhibits murine leukemia L1210 and human lymphocyte CEM cells at a 50% inhibitory concentration of 0.80-1.4 microM, respectively. EICAR causes a rapid and marked inhibition of inosinate (IMP) dehydrogenase (EC 1.1.1.205) activity in intact L1210 and CEM cells reflected by a concentration-dependent accumulation of IMP and depletion of GTP and dGTP levels. EICAR 5'-monophosphate is a potent inhibitor of purified L1210 cell IMP dehydrogenase (Ki/Km 0.06). Inhibition of IMP dehydrogenase by EICAR 5'-monophosphate is competitive with respect to IMP. L1210 cells that were selected for resistance to the cytostatic action of EICAR proved to be adenosine kinase-deficient. Also, studies with other mutant L1210 and CEM cell lines revealed that adenosine kinase, as well as an alternative pathway, may be responsible for the conversion of EICAR to its 5'-monophosphate. Purified 2'-deoxycytidine kinase, 2'-deoxyguanosine kinase, cytosolic 5'-nucleotidase, and nicotinamide dinucleotide (NAD) pyrophosphorylase do not seem to be markedly involved in the metabolism of EICAR.


Subject(s)
Antineoplastic Agents/pharmacology , Deoxyguanine Nucleotides/biosynthesis , Guanosine Triphosphate/biosynthesis , IMP Dehydrogenase/antagonists & inhibitors , Ribonucleosides/pharmacology , Adenosine/pharmacology , Animals , Cell Division/drug effects , Deoxyguanine Nucleotides/antagonists & inhibitors , Guanine/pharmacology , Guanosine/pharmacology , Guanosine Triphosphate/antagonists & inhibitors , Humans , Leukemia L1210/enzymology , Leukemia L1210/metabolism , Lymphocytes/metabolism , Mice , Mycophenolic Acid/pharmacology , Purine Nucleotides/metabolism , Ribavirin/analogs & derivatives , Ribavirin/pharmacology , Ribonucleotides/metabolism , Tumor Cells, Cultured
5.
Biochem Pharmacol ; 46(1): 69-77, 1993 Jul 06.
Article in English | MEDLINE | ID: mdl-8102234

ABSTRACT

[1-[2',5'-Bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3-N- methyl-thymine]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''- dioxide) (TSAO-m3T) is a potent, selective and specific inhibitor of human immunodeficiency virus type 1 replication in vitro. Uptake of TSAO-m3T by human CEM cells is drug concentration-dependent and increased proportionally with increasing initial extracellular TSAO-m3T concentrations up to 20 micrograms/mL. Within 6 hr of incubation, the cells were almost completely saturated with the test compound; further incubation up to 72 hr did not markedly increase the intracellular concentration of the compound. No intracellular metabolic conversion of TSAO-m3T was observed in CEM, MT-4 or MOLT-4 cells. Upon intravenous bolus administration of TSAO-m3T to mice at 0.75 mg/kg, TSAO-m3T was rapidly cleared from the plasma in a mono-exponential manner (half-life: 22 min; distribution volume: 9.5 L/kg; total body clearance: 17.8 L/hr/kg). TSAO-m3T mainly accumulated in the lungs, followed by the heart, kidney and liver. Significant amounts of different metabolites of TSAO-m3T were detected in most tissues, the liver, kidney and spleen being the organs that showed the most extensive metabolism. The principal metabolites identified were TSAO-m3T derivatives in which the t-butyldimethylsilyl moiety at C-2' and/or C-5' had been split off. The free base N3-methylthymine was not detected.


Subject(s)
Antiviral Agents/pharmacokinetics , HIV-1/drug effects , Spiro Compounds/pharmacology , Spiro Compounds/pharmacokinetics , Thymidine/analogs & derivatives , Animals , CD4-Positive T-Lymphocytes/drug effects , Cell Line/drug effects , Cell Line/metabolism , Half-Life , Humans , Metabolic Clearance Rate , Mice , Models, Chemical , Spiro Compounds/metabolism , Thymidine/metabolism , Thymidine/pharmacokinetics , Thymidine/pharmacology , Thymidine Kinase/metabolism , Thymidine Phosphorylase/metabolism , Tissue Distribution , Tritium , Uridine/analogs & derivatives
6.
J Biol Chem ; 268(9): 6332-7, 1993 Mar 25.
Article in English | MEDLINE | ID: mdl-8384209

ABSTRACT

After they have been transfected with the herpes simplex virus type 1 (HSV-1) or type 2 (HSV-2) thymidine kinase (TK) gene murine mammary carcinoma (FM3A) cells become highly sensitive to the growth inhibitory properties of the antiherpetic agents (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU), 9(-)[(2-hydroxyethoxy)methyl]guanine (acyclovir, ACV), 9(-)[(1,3-dihydroxy-2-propoxy)methyl]guanine (DHPG, ganciclovir), and 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-methyluracil (FMAU). BVDU was 100-fold more potent an inhibitor of HSV TK gene-transfected tumor cell growth (50% inhibitory concentration (IC50), 0.0020-0.0047 microM) than FMAU or DHPG (IC50, 0.051-0.277 microM) and 1000-fold more potent than ACV (IC50, 0.42-4.9 microM). As a rule, the test compounds were more cytostatic to HSV-2 TK than HSV-1 TK gene-transfected FM3A cells. This may be ascribed to the higher phosphorylating capacity (Vmax/Km) of HSV-2 TK than HSV-1 TK and/or to the higher TK enzyme levels of the HSV-2 TK gene-transfected FM3A cells than the HSV-1 TK gene-transfected FM3A cells. Thymidylate synthase of the HSV TK gene-transfected FM3A cells appears to be the target enzyme for the cytostatic action of BVDU, but not FMAU, DHPG, or ACV. Instead, the cytostatic activity of DHPG seems to be correlated with its conversion to the triphosphate form and subsequent incorporation into the DNA of HSV TK gene-transfected FM3A cells.


Subject(s)
Antiviral Agents/pharmacology , Bromodeoxyuridine/analogs & derivatives , Simplexvirus/genetics , Thymidine Kinase/genetics , Animals , Bromodeoxyuridine/pharmacology , Cell Division/drug effects , Humans , Mice , Molecular Structure , Phosphorylation , Simplexvirus/drug effects , Simplexvirus/enzymology , Thymidine Kinase/metabolism , Transfection , Tumor Cells, Cultured
7.
Eur J Biochem ; 206(2): 485-90, 1992 Jun 01.
Article in English | MEDLINE | ID: mdl-1597187

ABSTRACT

Thymidine kinase 2 (TK2), also called mitochondrial thymidine kinase, is a pyrimidine deoxyribonucleoside kinase expressed in all cells and tissues. It was recently purified to apparent homogeneity from human leukemic spleen and the active enzyme was shown to be a monomer of a 29-kDa polypeptide. The enzyme is feedback-inhibited by both end products, dCTP and dTTP. Here we show that TK2 purified from several different sources, including purified beef heart mitochondria, could be directly photoaffinity labeled with radioactive dTTP (approximately 18% of all TK2 molecules were cross-linked to dTTP after 20 min of ultraviolet irradiation) or to a lower extent with dCTP. Photo-incorporation was inhibited by the presence of the other effector but also the phosphate donor ATP blocked photolabeling, with dTTP. Addition of nucleoside substrates gave only a marginal inhibition of photo-incorporation. There were no detectable difference in the molecular size of photolabeled TK2 isolated from human spleen, brain or placenta, monkey liver, beef heart and beef heart mitochondria. Nor was there any significant differences in the enzyme kinetic properties of these enzymes. Cleavage of labeled TK2 with cyanogen bromide showed that dTTP was incorporated into a single 3-kDa peptide. TK2 was the only pyrimidine deoxynucleoside kinase expressed in liver, heart and brain. A detailed characterization of the subunit structure and substrate specificity of this enzyme is of importance for the design of new antiviral and cytostatic therapies based on nucleoside analogs.


Subject(s)
Affinity Labels , Isoenzymes/chemistry , Thymidine Kinase/chemistry , Thymine Nucleotides/chemistry , Animals , Autoradiography , Brain/enzymology , Cattle , Cyanogen Bromide/metabolism , Electrophoresis, Polyacrylamide Gel , Humans , Liver/enzymology , Male , Mitochondria, Heart/enzymology , Myocardium/enzymology , Photochemistry , Rats , Spleen/enzymology , Thymidine Kinase/isolation & purification
8.
Biochem Pharmacol ; 43(2): 197-206, 1992 Jan 22.
Article in English | MEDLINE | ID: mdl-1739408

ABSTRACT

Deoxycytidine (dCyd) kinase has been purified to homogeneity from human leukemic spleen, and the capacity of the enzyme to phosphorylate 2',3'-dideoxynucleoside (ddN) analogs that are clinically effective inhibitors of human immunodeficiency virus (HIV) replication was evaluated. Cytosine-containing ddN analogs, such as 2',3'-dideoxycytidine, 2',3'-dideoxy-2',3'-dehydrocytidine, and cytallene, were efficiently phosphorylated by dCyd kinase, while no phosphorylation of purine-containing ddN analogs was detected. dCyd kinase was completely inactive toward 2',3'-dideoxyadenosine (ddAdo), 2',3'-dideoxyinosine, 2',3'-dideoxyguanosine, and adenallene, although it was capable of phosphorylating both 2'-deoxyadenosine (dAdo) and 2'-deoxyguanosine (dGuo). The abilities of wild type and mutant human T lymphoblastoid CEM cells to accumulate ddAdo in situ and in vitro were also ascertained. Comparison of the abilities of intact wild type CEM cells and derivatives deficient in nucleoside transport, dCyd kinase, and/or adenosine (Ado) kinase to accumulate [3H]ddAdo-derived radioactivity revealed no significant differences among the wild type and mutant strains. However, ddAdo phosphorylating activity was decreased in extracts from Ado kinase-deficient cells but not in lysates prepared from cells genetically deficient in dCyd kinase activity. In comparative growth rate experiments, wild type, nucleoside transport-deficient, and dCyd kinase-deficient CEM cells were equally sensitive to ddAdo toxicity, while, interestingly, a deficiency in Ado kinase correlated with a 5-fold decreased growth sensitivity to the purine ddN. Insertion of an adenine phosphoribosyltransferase deficiency into the CEM cell lines did not influence ddAdo toxicity or incorporation rate. These results imply that Ado kinase may be an important factor in ddAdo phosphorylation by CEM cells. Furthermore, these studies demonstrate that cytosine- and purine-containing ddNs are transported and activated by independent pathways and, therefore, have important implications for anti-HIV therapy in that pyrimidine and purine ddNs might be used in combination for the treatment of acquired immunodeficiency syndrome.


Subject(s)
Antiviral Agents/metabolism , Deoxycytidine Kinase/antagonists & inhibitors , Dideoxynucleosides/metabolism , Adenine Phosphoribosyltransferase/deficiency , Cell Line/drug effects , Cell Line/metabolism , Chromatography, High Pressure Liquid , Deoxyadenosines/metabolism , Deoxycytidine/metabolism , Deoxycytidine Kinase/isolation & purification , Dideoxyadenosine/metabolism , Dideoxyadenosine/pharmacology , Dideoxynucleosides/isolation & purification , Humans , Phosphorylation , Substrate Specificity
9.
Biochem Pharmacol ; 42(9): 1829-36, 1991 Oct 09.
Article in English | MEDLINE | ID: mdl-1657002

ABSTRACT

Three key enzymes in the anabolic phosphorylation of deoxyribonucleosides and deoxyribonucleoside analogs were purified i.e. cytoplasmic thymidine kinase (TK1), mitochondrial thymidine kinase (TK2) and cytoplasmic deoxycytidine kinase (dCK) from human, mouse and monkey liver and spleen. Their subunit structure and substrate specificities were compared. Extensive purification of TK1 and dCK from mouse spleen and TK2 from mouse and monkey livers revealed major polypeptide bands of 25, 30 and 28 kD, respectively, on sodium dodecyl sulphate-polyacrylamide gel electrophoresis which are very similar to the subunit molecular weights of the corresponding human enzymes. Affinity purified polyclonal antibodies against human dCK also cross-reacted with 30 kD bands in extracts from both mouse and monkey spleen. Thus, the molecular weights of the subunits of these three enzymes appeared to be very similar in all three species. TK1 and TK2 from these different sources appeared to have similar substrate specificities against several deoxyribonucleoside analogs. However, mouse dCK differed significantly from monkey and human dCK in its capacity to phosphorylate dAdo and 2',3'-dideoxycytidine (ddCyd) with a Vmax approximately 10-fold lower than that of the two latter enzymes. The Km and Vmax values for dCyd and arabinocytosine appeared to be very similar with the enzymes from all three species. The fact that mouse dCK shows low activity with dAdo and ddCyd explains differences reported previously in the metabolism of dAdo and ddCyd in mouse compared to that in human lymphocytes. These results argue against the use of mice as model systems for human deoxynucleoside metabolism.


Subject(s)
Deoxycytidine Kinase/metabolism , Phosphotransferases/metabolism , Thymidine Kinase/metabolism , Animals , Chromatography, Affinity , Deoxycytidine Kinase/immunology , Deoxycytidine Kinase/isolation & purification , Haplorhini , Humans , Mice , Phosphorylation , Subcellular Fractions/metabolism , Substrate Specificity , Thymidine Kinase/isolation & purification
10.
FEBS Lett ; 280(2): 363-6, 1991 Mar 25.
Article in English | MEDLINE | ID: mdl-2013338

ABSTRACT

Existing data on the structure of human deoxycytidine kinase (dCK) diverge. A monomeric 60 kDa form has been isolated and the cloning of a cDNA coding for 626 amino acids corresponding to a 71 kDa protein has been reported. However, pure dCK isolated from leukemic spleen is a dimer of 30 kDa subunits. Amino acid sequences of peptides from digests of this protein are now presented. None of the peptide structures obtained correspond to the cDNA for the 71 kDa protein, but to a cDNA for a 30.5 kDa dCK recently cloned. Furthermore, homology of the peptide sequences od dCK to parts of thymidine kinases and protein-tyrosine kinases are detected.


Subject(s)
DNA/chemistry , Deoxycytidine Kinase/genetics , Amino Acid Sequence , Animals , Chromatography, High Pressure Liquid , Cloning, Molecular , Deoxycytidine Kinase/chemistry , Humans , Mice , Molecular Sequence Data , Protein-Tyrosine Kinases/chemistry , Protein-Tyrosine Kinases/genetics , Sequence Homology, Nucleic Acid , Spleen/chemistry , Thymidine Kinase/chemistry , Thymidine Kinase/genetics
11.
Exp Cell Res ; 178(2): 335-42, 1988 Oct.
Article in English | MEDLINE | ID: mdl-2844562

ABSTRACT

Deoxycytidine kinase specific activity was high in human peripheral lymphocytes and increased less than 2-fold when the lymphocytes were stimulated by phytohemagglutinin A. Ion-exchange chromatography showed the same profile of deoxycytidine kinase activity in resting and proliferating cells. This enzyme could also efficiently phosphorylate deoxyadenosine and deoxyguanosine. In contrast, the thymidine kinase activity was very low in resting peripheral lymphocytes and increased more than 40-fold upon stimulation. Similar relative changes in the activities of the two enzymes were observed in human T-lymphoblast cells (CCRF-CEM) separated by centrifugal elutriation into cells of different cell cycle phases. The ratio of deoxycytidine to thymidine kinase activities is 20:1 in extracts from resting human lymphocytes and 1:2 in PHA-stimulated cells. This drastic change in deoxyribonucleoside phosphorylating activities during the cell cycle in human lymphocytes is of importance for studies on unscheduled DNA synthesis, for the design of therapies to interfere with viral DNA metabolism, and for a correct interpretation of the compartmentation effects observed in DNA precursor metabolism.


Subject(s)
Cell Compartmentation , DNA/biosynthesis , Deoxycytidine Kinase/biosynthesis , Lymphocytes/enzymology , Phosphotransferases (Alcohol Group Acceptor) , Phosphotransferases/biosynthesis , Virus Replication , Cell Cycle , Cell Separation , Chromatography, DEAE-Cellulose , Chromatography, Ion Exchange , Deoxycytidine Kinase/metabolism , Flow Cytometry , Humans , Lymphocyte Activation , Lymphocytes/cytology , Lymphocytes/drug effects , Phosphorylation , Phosphotransferases/metabolism , Phytohemagglutinins/pharmacology , Thymidine Kinase/metabolism
12.
Biochemistry ; 27(12): 4258-65, 1988 Jun 14.
Article in English | MEDLINE | ID: mdl-2844225

ABSTRACT

Deoxycytidine kinase from human leukemic spleen has been purified 6000-fold to apparent homogeneity with an overall yield of 10%. The purification was achieved by using DEAE chromatography, hydroxylapatite chromatography, and affinity chromatography on dTTP-Sepharose. Only one form of deoxycytidine kinase activity was found during all the chromatographic procedures. The subunit molecular mass, as judged by sodium dodecyl sulfate--polyacrylamide gel electrophoresis, was 30 kilodaltons. The pure enzyme phosphorylates deoxycytidine, deoxyadenosine, and deoxyguanosine, demonstrating for the first time that the same enzyme molecule has the capacity to use these three nucleosides as substrates. The apparent molecular weight of the active enzyme, determined by gel filtration and glycerol gradient centrifugation, was 60,000. Thus, the active form of human deoxycytidine kinase is a dimer. The kinetic behavior of pure human deoxycytidine kinase was studied in detail with regard to four different phosphate acceptors and two different phosphate donors. The apparent Km values were 1, 20, 150, and 120 microM for deoxycytidine, arabinosylcytosine, deoxyguanosine, and deoxyadenosine, respectively. The Vmax values were 5-fold higher for the purine nucleosides as compared to the pyrimidine substrates. We observe competitive inhibition of the phosphorylation of one substrate by the presence of either of the three other substrates, but the apparent Ki values differed greatly from the corresponding Km values, suggesting the existence of allosteric effects. The double-reciprocal plots for ATP-MgCl2 as phosphate donor were convex, indicating negative cooperative effects. In contrast, plots with varying dTTP-MgCl2 concentration as phosphate donor were linear with an apparent Km of 2 microM. The enzyme activity was strongly inhibited by dCTP, in a noncompetitive way with deoxycytidine and in a competitive way with ATP-MgCl2.


Subject(s)
Deoxycytidine Kinase/isolation & purification , Leukemia/enzymology , Phosphotransferases/isolation & purification , Spleen/enzymology , Binding, Competitive , Chromatography, Ion Exchange , Deoxycytidine Kinase/analysis , Enzyme Stability , Humans , Kinetics
13.
Adv Exp Med Biol ; 195 Pt B: 311-4, 1986.
Article in English | MEDLINE | ID: mdl-3020911

ABSTRACT

The purification of deoxycytidine kinase from human leucemic spleen reported here result in a pure protein of molecular weight 28K. The enzyme eluates during gel filtration as a dimer and the same enzyme phosphorylates both deoxycytidine, deoxyguanosine and deoxyadenosine, but with different Km and Vmax values. Our results are in agreement with earlier studies with partially purified calf thymus deoxycytidine, but clearly different from some studies on human deoxycytidine kinase.


Subject(s)
Deoxycytidine Kinase/isolation & purification , Phosphotransferases/isolation & purification , Chromatography, Affinity , Deoxycytidine Kinase/metabolism , Humans , Molecular Weight , Spleen/enzymology
14.
Am J Optom Physiol Opt ; 57(9): 551-8, 1980 Sep.
Article in English | MEDLINE | ID: mdl-7425077

ABSTRACT

Accommodation and convergence normally bear a tight relation to each other. To the extent that night myopia is due to an actual change in lens convexity, accommodation in night myopia should be accompanied by a commensurate change in convergence. This prediction was shown to be false because of variability in the convergence mechanism.


Subject(s)
Accommodation, Ocular , Darkness/adverse effects , Myopia/etiology , Eye Movements , Humans , Vision Disorders/etiology
15.
Am Ind Hyg Assoc J ; 39(2): 94-9, 1978 Feb.
Article in English | MEDLINE | ID: mdl-637027

ABSTRACT

Neurotoxic agents such as MBK (2-hexanone) and MBK metabolites were fed in drinking water to guinea pigs. Effects of these solvents on locomotor activity were studied. Dynamic pupillometry indicated that MBK, 2,5-hexanedione and 2-hexanol decreased pupillary response throughout the first five weeks; by the 24th week, all treatment groups showed a greatly impaired pupillary response. From biotransformation studies, it is possible that the 2-hexanol effect on pupillary response may be attributed to its conversion to MBK and/or 2,5-hexanedione. Each of the solvents increased body weight, but decreased locomotor activity. The pupillary changes reported here may serve as an index of solvent exposure in the work environment, if such measurements were to be conducted on workers.


Subject(s)
Body Weight/drug effects , Ketones/pharmacology , Methyl n-Butyl Ketone/pharmacology , Reflex, Pupillary/drug effects , Animals , Guinea Pigs , Hexanols/metabolism , Hexanones/metabolism , Locomotion/drug effects , Methyl n-Butyl Ketone/adverse effects , Methyl n-Butyl Ketone/metabolism
16.
J Am Optom Assoc ; 48(7): 929-32, 1977 Jul.
Article in English | MEDLINE | ID: mdl-893939

ABSTRACT

Orthoptic therapy often entails the repetitive usage of detailed and complicated training procedures. Amblyopia and antisuppression therapy in particular may require weeks or months of trainning. A multipurpose training device has been constructed from commercially available components and promises to maintain a high level of patient interest and cooperation throughout the training procedure.


Subject(s)
Amblyopia/therapy , Orthoptics/methods , Television , Vision Disorders/therapy , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...